Download PDF
Geburtshilfe Frauenheilkd 2002; 62(10): 958-961
DOI: 10.1055/s-2002-35109
Übersicht

Georg Thieme Verlag Stuttgart · New York

Zur Hormonsubstitution beim malignen Melanom

Hormone Replacement Therapy in Women with Malignant MelanomaC. Keck, C. Tempfer, C. Knobloch, M. Breckwoldt
  • Universitäts-Frauenklinik Freiburg
Further Information

Publication History

Publication Date:
28 October 2002 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Beim malignen Melanom handelt es sich um einen Tumor, der von den pigmentbildenden Zellen der Haut ausgeht. Melanomzellen exprimieren teilweise und in unterschiedlichem Ausmaß Estrogenrezeptoren. In tierexperimentellen Untersuchungen konnte gezeigt werden, dass Sexualhormone einen Einfluss auf das Wachstumsverhalten von Melanomzellen ausüben. Es stellt sich daher die Frage, ob bei Frauen mit Melanomerkrankung die Zufuhr exogener Sexualhormone zulässig oder kontraindiziert ist.

Zu dieser Frage gibt es eine Reihe von epidemiologischen Studien, allerdings keine prospektive plazebokontrollierte und randomisierte Untersuchung. Aus den vorliegenden klinischen Studien lassen sich allerdings die folgenden Schlussfolgerungen und Empfehlungen ableiten: die Einnahme von Sexualhormonen erhöht weder das Risiko zur Entwicklung eines malignen Melanoms, noch hat sie einen ungünstigen Effekt auf den Verlauf und die Prognose einer bestehenden Melanom-Erkrankung.

Abstract

Malignant melanoma derives from pigmented cells of neuroectodermal origin. Melanoma cells express estrogen receptors. An influence of steroid hormones on the proliferation rate of melanoma cells was demonstrated in some animal experiments. Thus it is of concern whether or not women with malignant melanoma are candidates for hormone replacement therapy (HRT). Until today, no prospective randomized trial on the association between HRT and malignant melanoma has been published. However, from the data available from in vitro-studies, in vivo-studies, and epidemiological reports, we can draw the following conclusions: there is no convincing evidence that the intake of sexual steroids increases the risk for the development of malignant melanoma and there is no evidence that HRT, taken after a diagnosis of malignant melanoma, negatively influences the outcome of the disease.

Literatur

  • 1 Beral V, Ramcharan S, Faris R. Malignant melanoma and oral contraceptive use among women in California.  Br J Cancer. 1977;  36 804-809
    PubMedGoogle Scholar
  • 2 Stidham K R, Johnson J L, Seigler H F. Survival superiority of females with melanoma. A multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome.  Arch Surg. 1994;  129 316-324
    PubMedGoogle Scholar
  • 3 McGovern V J, Shaw H M, Milton G W, Farago G A. Prognostic significance of the histological features of malignant melanoma.  Histopathology. 1979;  3 385-393
    PubMedGoogle Scholar
  • 4 Shaw H M, Thompson J F. Superior survival of young women with malignant melanoma.  Am J Surg. 1999;  178 358
    CrossrefPubMedGoogle Scholar
  • 5 Cascinelli N, Bufalino R, Morabito A, Mackie R. Results of adjuvant interferon study in WHO melanoma programme.  Lancet. 1994;  343 913-914
    CrossrefPubMedGoogle Scholar
  • 6 Holly E A, Weiss N S, Liff J M. Cutaneous melanoma in relation to exogenous hormones and reproductive factors.  J Natl Cancer Inst. 1983;  70 827-831
    PubMedGoogle Scholar
  • 7 Wyshak G, Frisch R E, Albright N L, Albright T E, Schiff I. Reproductive factors and melanoma of the skin among women.  Int J Dermatol. 1989;  28 527-530
    CrossrefPubMedGoogle Scholar
  • 8 Green A, Bain C. Hormonal factors and melanoma in women.  Med J Aust. 1985;  142 446-448
    PubMedGoogle Scholar
  • 9 Holman C D, Armstrong B K, Heenan P J. Cutaneous malignant melanoma in women: exogenous sex hormones and reproductive factors.  Br J Cancer. 1984;  50 673-680
    PubMedGoogle Scholar
  • 10 Osterlind A, Tucker M A, Stone B J, Jensen O M. The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women.  Int J Cancer. 1988;  42 821-824
    PubMedGoogle Scholar
  • 11 Zanetti R, Franceschi S, Rosso S, Bidoli E, Colonna S. Cutaneous malignant melanoma in females: the role of hormonal and reproductive factors.  Int J Epidemiol. 1990;  19 522-526
    PubMedGoogle Scholar
  • 12 Diaz L C, Das Gupta T K, Beattie C W. Effects of gonadal steroids on melanocytes in developing hamsters.  Pediatr Dermatol. 1986;  3 247-256
    PubMedGoogle Scholar
  • 13 Ferno M, Borg A, Ingvar C, Jonsson P E. Estrogen receptor and binding site for estramustine in metastatic malignant melanoma.  Anticancer Res. 1987;  7 741-743
    PubMedGoogle Scholar
  • 14 Walker M J, Beattie C W, Patel M K, Ronan S M, Das Gupta T K. Estrogen receptor in malignant melanoma.  J Clin Oncol. 1987;  5 1256-1261
    PubMedGoogle Scholar
  • 15 Hitselberger M H, Schleicher R L, Beattie C W. Effects of estradiol on estrogen receptor, progesterone receptor, and tyrosinase in hamster melanoma transplanted into athymic mice.  Cancer Res. 1988;  48 3720-3727
    PubMedGoogle Scholar
  • 16 Schleicher R L, Hitselberger M H, Beattie C W. Inhibition of hamster melanoma growth by estrogen.  Cancer Res. 1987;  47 453-459
    PubMedGoogle Scholar
  • 17 Markland F S, Horn D. Steroid hormone receptor studies in melanoma model systems.  J Supramol Struct. 1980;  13 35-46
    CrossrefPubMedGoogle Scholar
  • 18 Proctor J W, Yamamura Y, Gaydos D, Mastromatteo W. Further studies on endocrine factors and the growth and spread of B16 melanoma.  Oncology. 1981;  38 102-105
    PubMedGoogle Scholar
  • 19 Feucht K A, Walker M J, Das Gupta T K, Beattie C W. Effect of 17 beta-estradiol on the growth of estrogen receptor-positive human melanoma in vitro and in athymic mice.  Cancer Res. 1988;  48 7093-7101
    PubMedGoogle Scholar
  • 20 Simon S R, Ershler W B. Hormonal influences on growth of B16 murine melanoma.  J Natl Cancer Inst. 1985;  74 1085-1088
    PubMedGoogle Scholar
  • 21 Cobb J P, McGrath A. In vitro effects of melanocyte-stimulating hormone, adrenocorticotropic hormone, 17 beta-estradiol, or testosterone propionate on Cloudman S91 mouse melanoma cells.  J Natl Cancer Inst. 1974;  52 567-570
    PubMedGoogle Scholar
  • 22 Kline E L, Smith T J, Carland K A, Blackmon B. Inhibition of imidazole-induced tyrosinase activity by estradiol and estriol in cultured B16/C3 melanoma cells.  J Cell Physiol. 1988;  134 497-502
    CrossrefPubMedGoogle Scholar
  • 23 Proctor J W, Auclair B G, Stokowski L. Endrocrine factors and the growth and spread of B16 melanoma.  J Natl Cancer Inst. 1976;  57 1197-1198
    PubMedGoogle Scholar
  • 24 Beattie C W, Ronan S G, Amoss M S. Estrogens influence the natural history of Sinclair swine cutaneous melanoma.  Cancer Res. 1991;  51 2025-2028
    PubMedGoogle Scholar
  • 25 Santen R J, Santner S J, Harvey H A, Lipton A, Simmonds M, Feil P D, Manders E, Davis T S. Marked heterogeneity of aromatase activity in human malignant melanoma tissue.  Eur J Cancer Clin Oncol. 1988;  24 1811-1816
    CrossrefPubMedGoogle Scholar
  • 26 Walker M J, Chaudhuri P K, Das Gupta T K, Beattie C W. Influence of host sex on the growth of human melanoma.  Proc Soc Exp Biol Med. 1980;  165 96-99
    PubMedGoogle Scholar
  • 27 Kanda N, Watanabe S. 17 beta-estradiol, progesterone, and dihydrotestosterone suppress the growth of human melanoma by inhibiting interleukin-8 production.  J Invest Dermatol. 2001;  117 274-283
    CrossrefPubMedGoogle Scholar
  • 28 Pack G T, Scharnagel M. The prognosis for malignant melanoma in the pregnant woman.  Cancer. 1951;  4 324-334
    PubMedGoogle Scholar
  • 29 Holly E A. Melanoma and pregnancy. Recent Results.  Cancer Res. 1986;  102 118-126
    PubMedGoogle Scholar
  • 30 Holman C D, Armstrong B K, Heenan P J. Cutaneous malignant melanoma in women: exogenous sex hormones and reproductive factors.  Br J Cancer. 1984;  50 673-680
    PubMedGoogle Scholar
  • 31 Osterlind A, Tucker M A, Stone B J, Jensen O M. The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women.  Int J Cancer. 1988;  42 821-824
    PubMedGoogle Scholar
  • 32 Hartge P, Tucker M A, Shields J A, Augsburger J, Hoover R N, Fraumeni J F. Case-control study of female hormones and eye melanoma.  Cancer Res. 1989;  49 4622-4625
    PubMedGoogle Scholar
  • 33 Bork K, Brauninger W. Prior pregnancy and melanoma survival.  Arch Dermatol. 1986;  122 1097
    PubMedGoogle Scholar
  • 34 Kie R M, Bufalino R, Morabito A, Sutherland C, Cascinelli N. Lack of effect of pregnancy on outcome of melanoma. For The World Health Organisation Melanoma Programme.  Lancet. 1991;  37 653-655
    PubMedGoogle Scholar
  • 35 Travers R L, Sober A J, Berwick M, Mihm M C, Barnhill R L, Duncan L M. Increased thickness of pregnancy-associated melanoma.  Br J Dermatol. 1995;  132 876-883
    PubMedGoogle Scholar
  • 36 Beral V, Ramcharan S, Faris R. Malignant melanoma and oral contraceptive use among women in California.  Br J Cancer. 1977;  36 804-809
    PubMedGoogle Scholar
  • 37 Grin C M, Driscoll M S, Grant-Kels J M. The relationship of pregnancy, hormones, and melanoma.  Semin Cutan Med Surg. 1998;  17 167-171
    PubMedGoogle Scholar
  • 38 Adami H O, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy.  Int J Cancer. 1989;  44 833-839
    CrossrefPubMedGoogle Scholar
  • 39 Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort.  Int J Cancer. 1996;  67 327-332
    CrossrefPubMedGoogle Scholar
  • 40 Holly E A, Weiss N S, Liff J M. Cutaneous melanoma in relation to exogenous hormones and reproductive factors.  J Natl Cancer Inst. 1983;  70 827-831
    PubMedGoogle Scholar
  • 41 Gallagher R P, Elwood J M, Hill G B, Coldman A J, Threlfall W J, Spinelli J J. Reproductive factors, oral contraceptives and risk of malignant melanoma: Western Canada Melanoma Study.  Br J Cancer. 1985;  52 901-907
    PubMedGoogle Scholar
  • 42 Holman C D, Armstrong B K, Heenan P J. Cutaneous malignant melanoma in women: exogenous sex hormones and reproductive factors.  Br J Cancer. 1984;  50 673-680
    PubMedGoogle Scholar
  • 43 Beral V, Evans S, Shaw H, Milton G. Oral contraceptive use and malignant melanoma in Australia.  Br J Cancer. 1984;  50 681-685
    PubMedGoogle Scholar
  • 44 Holly E A, Cress R D, Ahn D K. Cutaneous melanoma in women: ovulatory life, menopause, and use of exogenous estrogens.  Cancer Epidemiol Biomarkers Prev. 1994;  3 661-668
    PubMedGoogle Scholar
  • 45 Beral V, Ramcharan S, Faris R. Malignant melanoma and oral contraceptive use among women in California.  Br J Cancer. 1977;  36 804-809
    PubMedGoogle Scholar
  • 46 Lederman J S, Lew R A, Koh H K, Sober A J. Influence of estrogen administration on tumor characteristics and survival in women with cutaneous melanoma.  J Natl Cancer Inst. 1985;  74 981-985
    PubMedGoogle Scholar
  • 47 Shaw H M, Milton G W, Farago G, McCarthy W H. Endocrine influences on survival from malignant melanoma.  Cancer. 1978;  42 669-677
    PubMedGoogle Scholar

PD Dr. C. Keck Leitender Oberarzt

Universitäts-Frauenklinik Freiburg

Hugstetter Straße 55

79106 Freiburg

Email: ckeck@frk.ukl.uni-freiburg.de

      >